Metabolic diseases.
Balfe
Andrew
A
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. andrew.balfe@thomson.com
Perry
Letitia
L
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D056657:Cathepsin K; D002403:Cathepsins / Q000037:antagonists & inhibitors; D002621:Chemistry; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D010024:Osteoporosis / Q000188:drug therapy*; D012958:Societies, Scientific; D014481:United States
D019440:Anti-Obesity Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K